Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. develops oral drug delivery technology for drugs commonly delivered by injection. Its Protein Oral Delivery, or POD, platform is designed to protect therapeutic proteins in the gastrointestinal tract and improve absorption, with company updates centered on oral insulin development and related clinical-stage programs.
Oramed news also covers its expanded strategic investment activity, including positions and agreements involving Scilex and Alpha Tau Medical, as well as financial results, cash returns, dividend actions, shareholder rights matters, and other capital-structure developments. Recurring announcements connect the company’s pharmaceutical platform with its investment portfolio, governance actions, and operating expenses.
Oramed Pharmaceuticals' subsidiary, Oravax Medical, announced positive preliminary data from its Phase 1 trial for an oral Covid-19 vaccine. The trial met both safety and immunogenicity endpoints, showing a significant antibody response in the majority of patients. No safety issues were reported. The oral vaccine utilizes a triple antigen VLP design that targets crucial SARS-CoV-2 proteins, aiming for a protective response against existing and emerging strains. This proof-of-concept trial involves 24 healthy volunteers, with results expected over a 24-week monitoring period.
Oramed Pharmaceuticals reported positive outcomes from its Phase 2 trial of ORMD-0801, an oral insulin for Type 2 Diabetes patients with NASH, conducted with 32 patients over 12 weeks. Primary endpoint met: ORMD-0801 showed safety and tolerability at 8 mg twice daily. Secondary endpoint met: Demonstrated a significant reduction in liver fat content, suggesting its potential to treat NASH effectively. The firm anticipates forthcoming results from its Phase 3 trial in January 2023, highlighting the importance of ORMD-0801 in addressing a serious unmet medical need.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced that CEO Nadav Kidron will present an overview of the company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 3:00 p.m. ET, in New York. The presentation will highlight Oramed’s innovations in oral drug delivery systems, particularly its lead candidate, ORMD-0801, aimed at transforming diabetes treatment. The presentation will be accessible for 90 days via a provided link.
Oramed Pharmaceuticals announced that its Phase 3 trial, ORA-D-013-2, has reached over 50% enrollment of the targeted 450 patients for its oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes. This trial follows the completion of enrollment for the larger ORA-D-013-1 trial, which involved 710 patients. The trials mark the first Phase 3 oral insulin studies conducted under FDA oversight. The primary goal of ORA-D-013-2 is to assess the efficacy of ORMD-0801 compared to placebo in improving glycemic control over a 26-week period.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that it will provide a company overview and updates at the Canaccord Genuity Annual Growth Conference in Boston, Massachusetts, from August 8-11, 2022. The presentation is scheduled for August 10 at 4:30 p.m. E.T. and will be webcasted, with a link available on the Oramed website 48 hours prior. Oramed focuses on oral drug delivery systems and aims to revolutionize diabetes treatment with its lead candidate, ORMD-0801, currently in pivotal Phase 3 studies.
Oramed Pharmaceuticals reported a strong financial position with $169 million in cash and no debt as of March 31, 2022. The company expects pivotal Phase 3 oral insulin data in January 2023 and Phase 2 NASH data soon. ORMD-0801 aims to revolutionize type 2 diabetes treatment, offering a non-injection method beneficial to patients. Additionally, Oravax's Phase 1 clinical trial for an oral COVID-19 vaccine is underway in South Africa, with top-line data expected later this year. Oramed feels well-positioned for upcoming milestones despite broader market challenges.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced the addition of Dr. Anne Peters to its Scientific Advisory Board on June 1, 2022. Dr. Peters, a leading expert in diabetes care, brings extensive experience in clinical diabetes programs and research. She has authored over 200 publications and has been involved in over 40 research studies. The company is advancing its pivotal Phase 3 studies for ORMD-0801, the first oral insulin capsule aimed at transforming diabetes treatment. This strategic appointment aims to enhance Oramed's scientific direction and development capabilities.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced a significant achievement on May 24, 2022, as the US Patent and Trademark Office granted them a patent for methods and compositions aimed at treating diabetes mellitus. This patent covers oral pharmaceutical solutions that combine insulin with Glucagon-like Peptide 1 (GLP-1). Oramed is pioneering oral delivery systems to transform diabetes treatment, particularly with its lead candidate, ORMD-0801, currently in pivotal Phase 3 trials, along with the development of an oral GLP-1 analog capsule, ORMD-0901.
Oramed Pharmaceuticals (Nasdaq:ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, in Miami, Florida. The presentation is set for 12:00 p.m. E.T. and will be available for streaming for 90 days. Known for its oral drug delivery innovations, Oramed aims to transform diabetes treatment with its lead candidate, ORMD-0801, currently in Phase 3 trials.
Oramed Pharmaceuticals has completed enrollment for its Phase 3 ORA-D-013-1 study of the oral insulin capsule, ORMD-0801, with 710 patients, exceeding the initial goal of 675. This study focuses on type 2 diabetes patients with inadequate glycemic control, aiming for efficacy results in January 2023. The oral insulin could significantly improve patient experience and outcomes compared to injectable insulin, potentially becoming the first FDA-approved oral insulin.